Years Active: 2025
Title: Jochen Beninga: Innovator in Immunotherapy
Introduction
Jochen Beninga is a notable inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of immunotherapy, particularly in the development of multifunctional binding proteins. His work focuses on enhancing the efficacy of treatments for proliferative disorders, including multiple myeloma.
Latest Patents
Beninga holds a patent for "Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering." This patent describes multifunctional binding proteins that consist of a first and a second antigen binding domain (ABD) along with an immunoglobulin Fc region or its variant. The first ABD specifically binds to human BCMA, while the second ABD binds to human NKp46. Additionally, the Fc region is designed to bind to a human Fc-γ receptor. This innovation has potential applications in the treatment and prevention of proliferative disorders, including multiple myeloma.
Career Highlights
Throughout his career, Jochen Beninga has focused on advancing therapeutic strategies that leverage the immune system. His research has contributed to a deeper understanding of how binding proteins can be engineered to improve treatment outcomes for patients with serious health conditions.
Collaborations
Beninga has collaborated with notable colleagues, including Nicolas Gourdin and Laurent Gauthier. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of their collective research efforts.
Conclusion
Jochen Beninga is a pioneering inventor whose work in immunotherapy is paving the way for innovative treatments for proliferative disorders. His patent on NK cell engagers exemplifies the potential of engineered binding proteins in modern medicine.